Clinical Trials on Schnitzler Syndrome

Total 34041 results

GlaxoSmithKline
Parexel

Terminated

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndrome

United States, Spain
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Amifostine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Sunnybrook Health Sciences Centre
Novartis

Terminated

Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Canada
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaborators

Completed

Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes (MDS04)

Myelodysplastic Syndromes

France
Institut Paoli-Calmettes

Unknown

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) (QPL-MDS)

Myelodysplastic Syndromes

France
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Myelodysplastic Syndromes

Spain
Roswell Park Cancer Institute
Genzyme, a Sanofi Company

Terminated

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Myelodysplastic Syndrome

United States
University of Rochester

Completed

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
TetraLogic Pharmaceuticals

Completed

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

Myelodysplastic Syndrome

United States
Washington University School of Medicine

Completed

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Myelodysplastic Syndromes

United States
Seoul St. Mary's Hospital
Celgene Corporation

Unknown

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Eisai Inc.

Terminated

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Janssen Korea, Ltd., Korea

Completed

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Korea, Republic of
Technische Universität Dresden
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Temsirolimus in Myelodysplastic Syndrome (MDS) (TEMDS)

Myelodysplastic Syndrome

Germany
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Università degli Studi di Brescia
University of Bologna; University of Udine; University of Genova; University of... and other collaborators

Completed

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (MDSAZA0706)

Myelodysplastic Syndrome

Italy
Rush University Medical Center
H. Lundbeck A/S

Terminated

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Myelodysplastic Syndrome

United States
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Arno Therapeutics

Unknown

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Samsung Medical Center

Unknown

Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Cttq

Unknown

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome (DREAM)

Myelodysplastic Syndrome

China
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Withdrawn

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes (CLO2009AISSM05)

Myelodysplastic Syndromes

Italy
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Gemin X

Completed

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Canada, United States
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Duke University
Eisai Inc.; Cephalon

Completed

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Tel-Aviv Sourasky Medical Center

Unknown

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (ViLen 001)

Myelodysplastic Syndrome

Israel
M.D. Anderson Cancer Center

Completed

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Myelodysplastic Syndrome

United States
Veeda Oncology
Cephalon

Terminated

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Centre Hospitalier Universitaire de Nice

Terminated

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

Myelodysplastic Syndromes

France
Fondazione Amelia Scorza Onlus

Unknown

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (O-MDS-Protocol)

Myelodysplastic Syndrome

Italy
Shandong University
National Natural Science Foundation of China

Unknown

Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
medac GmbH

Completed

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Finland
Fundacion para el Estudio de la Hematologia y Hemoterapia...

Terminated

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Myelodysplastic Syndrome

Spain
Telik

Completed

Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Institutes of Health Clinical Center (CC)

Completed

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Myelodysplastic Syndromes | Hematologic Diseases

United States
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France

Clinical Trials on Schnitzler Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations